3-(3,5-Difluorophenyl)-4-[3-[3-(2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-7-yl)propyl]-1,2,4-oxadiazol-5-yl]butanoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(3,5-Difluorophenyl)-4-[3-[3-(2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazepin-7-yl)propyl]-1,2,4-oxadiazol-5-yl]butanoic acid
• 化学式: C₂₃H₂₄F₂N₄O₄
• 分子量: 458.5
• InChiKey: VNABBIMAAHCJJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• Heteroarylalkanoic acids as integrin receptor antagonists derivatives
  申请人：Boys L. Mark

  公开号：US20050043344A1

  公开（公告）日：2005-02-24

  The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.

  本发明涉及包含式I的化合物或其药学上可接受的盐的制药组合物，以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法，而不显著抑制αVβ6整合素。
• HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Pharmacia Corporation

  公开号：EP1592421A1

  公开（公告）日：2005-11-09
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES
  申请人：Reiser Jochen

  公开号：US20100297139A1

  公开（公告）日：2010-11-25

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• Methods and Compositions for the Treatment of Proteinuric Diseases
  申请人：The General Hospital Corporation

  公开号：US20160296592A1

  公开（公告）日：2016-10-13

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.
• Methods and Compositions For the Treatment of Proteinuric Diseases
  申请人：The General Hospital Corporation

  公开号：US20180344803A1

  公开（公告）日：2018-12-06

  The present invention is directed to methods of treating proteinuric diseases by the administration of avβ3 integrin inhibitors.